Ashiuchi M, Tani K, Soda K & Misono H (1998) Properties of
glutamate racemase from Bacillus subtilis IFO 3336 producing
poly-gamma-glutamate. J Biochem (Tokyo) 123: 1156–1163.
Banerjee A, Dubnau E, Quemard A et al. (1994) InhA, a gene
encoding a target for isoniazid and ethionamide in
Mycobacterium tuberculosis. Science 263: 227–230.
Barreto ML, Pereira SM & Ferreira AA (2006) BCG vaccine:
efficacy and indications for vaccination and revaccination.
J Pediatr (Rio J) 82: S45–S54.
Bhatt A, Fujiwara N, Bhatt K et al. (2007) Deletion of kasB in
Mycobacterium tuberculosis causes loss of acid-fastness and
subclinical latent tuberculosis in immunocompetent mice.
Proc Natl Acad Sci USA 104: 5157–5162.
Born TL & Blanchard JS (1999) Structure/function studies on
enzymes in the diaminopimelate pathway of bacterial cell wall
biosynthesis. Curr Opin Chem Biol 3: 607–613.
C´aceres NE, Harris NB, Wellehan JF, Feng Z, Kapur V & Barletta
RG (1997) Overexpression of the D-alanine racemase gene
confers resistance to D-cycloserine in Mycobacterium
smegmatis. J Bacteriol 179: 5046–5055.
Chambers HF, Moreau D, Yajko D et al. (1995) Can penicillins
and other beta-lactam antibiotics be used to treat tuberculosis?
Antimicrob Agents Chemother 39: 2620–2624.
Cirilli M, Zheng R, Scapin G & Blanchard JS (1998) Structural
symmetry: the three-dimensional structure of Haemophilus
influenzae diaminopimelate epimerase. Biochemistry 37:
16452–16458.
Dye C (2006) Global epidemiology of tuberculosis. Lancet 367:
938–940.
Gallo KA & Knowles JR (1993) Purification, cloning, and cofactor
independence of glutamate racemase from Lactobacillus.
Biochemistry 32: 3981–3990.
Gao LY, Laval F, Lawson EH et al. (2003) Requirement for kasB in
Mycobacterium mycolic acid biosynthesis, cell wall
impermeability and intracellular survival: implications for
therapy. Mol Microbiol 49: 1547–1563.
Glavas S & Tanner ME (1999) Catalytic acid/base residues of
glutamate racemase. Biochemistry 38: 4106–4113.
Goffin C & Ghuysen JM (2002) Biochemistry and comparative
genomics of SxxK superfamily acyltransferases offer a clue to
the mycobacterial paradox: presence of penicillin-susceptible
target proteins versus lack of efficiency of penicillin as
therapeutic agent. Microbiol Mol Biol Rev 66: 702–738.
Hartmann M, Tauch A, Eggeling L, Bathe B, Mockel B, Puhler A
& Kalinowski J (2003) Identification and characterization of
the last two unknown genes, dapC and dapF, in the succinylase
branch of the L-lysine biosynthesis of Corynebacterium
glutamicum. J Biotechnol 104: 199–211.
HigginsW, Tardif C, Richaud C, Krivanek MA & Cardin A (1989)
Expression of recombinant diaminopimelate epimerase in
Escherichia coli. Isolation and inhibition with an irreversible
inhibitor. Eur J Biochem 186: 137–143.
Kaufmann SH & Parida SK (2007) Changing funding patterns in
tuberculosis. Nat Med 13: 299–303.
Koo CW & Blanchard JS (1999) Chemical mechanism of
Haemophilus influenzae diaminopimelate epimerase.
Biochemistry 38: 4416–4422.
Koo CW, Sutherland A, Vederas JC & Blanchard JS (2000)
Identification of active site cysteine residues that function as
general bases: diaminopimelate epimerase. J Am Chem Soc
122: 6122–6123.
Kremer L, Dover LG, Morbidoni HR et al. (2003) Inhibition of
inhA activity, but not kasA activity, induces formation of a
kasA-containing complex in mycobacteria. J Biol Chem 278:
20547–20554.
Lloyd AJ, Huyton T, Turkenburg J & Roper DI (2004) Refinement
of Haemophilus influenzae diaminopimelic acid epimerase
(dapF) at 1.75 A resolution suggests a mechanism for
stereocontrol during catalysis. Acta Crystallogr D Biol
Crystallogr 60: 397–400.
Pillai B, Cherney MM, Diaper CM, Sutherland A, Blanchard JS,
Vederas JC & James MN (2006) Structural insights into
stereochemical inversion by diaminopimelate epimerase: an
antibacterial drug target. Proc Natl Acad Sci USA 103: 8668–8673.
Richaud C, Higgins W, Mengin-Lecreulx D & Stragier P (1987)
Molecular cloning, characterization, and chromosomal
localization of dapF, the Escherichia coli gene for
diaminopimelate epimerase. J Bacteriol 169: 1454–1459.
Rudnick G & Abeles RH (1975) Reaction mechanism and
structure of the active site of proline racemase. Biochemistry
14: 4515–4522.
Ruiz RC (1964) D-cycloserine in the treatment of pulmonary
tuberculosis resistant to the standard drugs: a study of 116
cases. Dis Chest 45: 181–186.
Schleifer KH & Kandler O (1972) Peptidoglycan types of bacterial
cell walls and their taxonomic implications. Bacteriol Rev 36:
407–477.
Takayama K & Kilburn JO (1989) Inhibition of synthesis of
arabinogalactan by ethambutol in Mycobacterium smegmatis.
Antimicrob Agents Chemother 33: 1493–1499.
Tanner ME (2002) Understanding nature’s strategies for enzymecatalyzed
racemization and epimerization. Acc Chem Res 35:
237–246.
Tanner ME, Gallo KA & Knowles JR (1993) Isotope effects
and the identification of catalytic residues in the reaction
catalyzed by glutamate racemase. Biochemistry 32:
3998–4006.
Usha V, Dover LG, Roper DL, Lloyd AJ & Besra GS (2006) Use of
a codon alteration strategy in a novel approach to cloning the
Mycobacterium tuberculosis diaminopimelic acid epimerase.
FEMS Microbiol Lett 262: 39–47.
Vilcheze C, Wang F, Arai M et al. (2006) Transfer of a point
mutation in Mycobacterium tuberculosis inhA resolves the
target of isoniazid. Nat Med 12: 1027–1029.
Wietzerbin J, Das BC, Petit JF, Lederer E, Leyh-Bouille M &
Ghuysen JM (1974) Occurrence of D-alanyl-(D)-mesodiaminopimelic
acid and meso-diaminopimelyl-mesodiaminopimelic
acid interpeptide linkages in the
peptidoglycan of Mycobacteria. Biochemistry 13:
3471–3476.
Winder FGA, Collins P & Rooney SA (1970) Effects of isoniazid
on mycolic acid synthesis in Mycobacterium tuberculosis and
on its cell envelope. Biochem J 117: P27.
Wiseman JS & Nichols JS (1984) Purification and properties of
diaminopimelic acid epimerase from Escherichia coli. J Biol
Chem 259: 8907–8914.